Medicare coverage of weight-loss drugs would drive up costs by billions of dollars

President Joe Biden’s proposal to have GLP-1 weight-loss drugs such as Ozempic and Mounjaro covered by Medicare and Medicaid would help tackle the public-health crisis of obesity, but it would raise the costs for the government programs by billions of dollars per year.